Gene therapy trial shows promise for lowering cholesterol with single injection

A groundbreaking gene-editing therapy, VERVE-102, is offering new hope for individuals struggling with high cholesterol. Early clinical trials in the UK reveal that a single injection can significantly reduce LDL cholesterol, commonly known as "bad" cholesterol. In some participants, this experimental treatment lowered LDL by as much as 62%, with the effects sustained for at least a year, and in some cases, up to 18 months.

“

The lowest dose lowered LDL by an average of 9%, while the highest dose lowered it by 62%.

This approach marks a departure from traditional daily medications like statins. VERVE-102 targets the PCSK9 gene in liver cells. PCSK9 normally hinders the liver's ability to clear LDL from the blood. By deactivating this gene, the therapy enhances the liver's LDL clearance, leading to lower cholesterol levels. Researchers are essentially aiming to replicate the protective effect seen in individuals with a natural genetic variation that results in lower cholesterol and reduced heart disease risk.

“

This approach marks a departure from traditional daily medications like statins. VERVE-102 targets the PCSK9 gene in liver cells.

While these initial findings, published in The New England Journal of Medicine, are encouraging, the research is still in its early Phase 1 clinical trial stage with only 35 participants. The study did not report dose-limiting toxicity, but some patients experienced mild to moderate infusion reactions, transient elevations in liver function tests, and one case of aspiration pneumonia. Scientists emphasize that this is not yet a cure for high cholesterol and that larger, long-term studies are essential to verify the therapy's sustained efficacy and its ability to ultimately reduce the risk of cardiovascular events like heart attacks and strokes.

“

While these initial findings are encouraging, the research is still in its early Phase 1 clinical trial stage with only 35 participants.